Our experience

We provide our clients with competent and experienced professionals
who have followed a rigorous selection process

We are aware that our experts can be strong assets in the development of new drugs for patients. We therefore owe it to wisely ourselves not only to select them according to the needs of our clients, but also to support them and to train them throughout their missions.

Therapeutic areas

Mucopolysaccharidosis (MPS)
Neuromuscular disorders
Peripheral Neuropathies
Genetic nephropathies
Primary immune deficiencies
Ono-hematological diseases

Activities

Clinical development plan
Protocol design
KOLs & Experts management
Site identification
Clinical study feasibility
Extension studies
Regulatory submissions
Phase Ib-II-III studies set-up & monitoring

Products

Gene therapy / Cell therapy / CAR-T cell therapy
IVIg / Immunotherapy / Enteric biotherapy
Small molecule repositioning

Phase I-III Clinical Trials
Phase I               Phase II                               Phase III 53%
Observational Studies
13%
Patient Support Programs
7%
Medical Affairs
10%
Consulting Services
17%
1 +
patients enrolled
1
clinical trials

conducted in

1
countries
1 +
sites